Timolol recall

Article

Bottles of timolol ophthalmic solution 0.25% and 0.5% (Sandoz Canada Inc.) have been recalled in Canada because of an increased risk of adverse events.

Bottles of timolol ophthalmic solution 0.25% and 0.5% (Sandoz Canada Inc.) have been recalled in Canada because of an increased risk of adverse events. Health Canada issued a warning after it emerged that some bottles of the intraocular pressure (IOP) lowering drops contained a higher-than-indicated level of active ingredient timolol maleate.

The excess timolol maleate could induce adverse events including red eye, irritation, blepharitis, keratitis, ptosis, and diplopia. Other non-ocular potential adverse events include dizziness, headache, bradycardia, hypotension, shortness of breath, difficulty breathing and cardiac failure.

Patients currently using the products have been advised to discontinue treatment immediately and return the bottle to their pharmacist. Sandoz has recalled the products; Health Canada will continue to monitor the situation. Currently, no adverse events relating to the mislabelled products have been noted.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.